Wird geladen...
Optimal design of trials to demonstrate the utility of genomically‐guided therapy: Putting Precision Cancer Medicine to the test
The new age of Precision Cancer Medicine, with specific biomarkers being used to direct targeted agents, generally concerns only a subset of patients within a certain histopathologically defined tumor type. This paradigm is challenged by the need to perform widespread molecular screening in certifie...
Gespeichert in:
| Veröffentlicht in: | Mol Oncol |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
John Wiley and Sons Inc.
2014
|
| Schlagworte: | |
| Online Zugang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5528747/ https://ncbi.nlm.nih.gov/pubmed/25081646 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.molonc.2014.06.014 |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|